Scarica l'app Stockscreener
72.87
0.05%
-0.04
Precedente Chiudi:
$72.91
Aprire:
$72.9
Volume 24 ore:
2.27M
Relative Volume:
1.04
Capitalizzazione di mercato:
$11.26B
Reddito:
$10.73M
Utile/perdita netta:
$-455.74M
Rapporto P/E:
-20.49
EPS:
-3.5569
Flusso di cassa netto:
$-502.70M
1 W Prestazione:
-0.04%
1M Prestazione:
+0.61%
6M Prestazione:
+57.90%
1 anno Prestazione:
+120.68%
Intervallo 1D:
$72.75
$73.00
Intervallo di 1 settimana:
$72.69
$73.01
Portata 52W:
$21.51
$73.06
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.87 | 11.26B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Roth Capital | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Does Avidity Biosciences Inc. have strong EBITDA marginsJuly 2025 Trends & Free High Return Stock Watch Alerts - mfd.ru
Volume Report: How does Avidity Biosciences Inc compare to its peersAnalyst Downgrade & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Avidity Biosciences, Inc. $RNA Shares Acquired by Candriam S.C.A. - MarketBeat
Avidity Biosciences prices $600M stock offering - MSN
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Avidity Biosciences (RNA) - The Globe and Mail
(RNA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Key facts: JPMorgan raises concerns on Novartis outlook; Novartis to acquire Avidity - TradingView
Avidity Biosciences Announces Expected Record Date for Spin-Off - TradingView
Avidity Biosciences stock hits all-time high at 72.74 USD By Investing.com - Investing.com Australia
Avidity Biosciences receives FTC clearance for Novartis merger - MSN
Novartis (NVS) Acquisition of Avidity Biosciences Moves Forward - GuruFocus
Avidity Biosciences Sets February 15, 2026 as Record Date for Planned Spin-Off - geneonline.com
Avidity holders to get Atrium cardiology SpinCo shares in Novartis deal - stocktitan.net
Avidity Biosciences says record date set for February 12, 2026 for spin-off - marketscreener.com
Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off - TradingView
Avidity Biosciences Announces Share Distribution for Spin-Off - Intellectia AI
Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at 72.74 USD - Investing.com
New York State Common Retirement Fund Purchases 120,365 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Atle Fund Management AB Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Avidity Biosciences Sets February Vote on $72-per-Share Novartis Takeover and Cardiology Spin-Off - TipRanks
Risk Recap: Whats the fair value of Avidity Biosciences Inc stock2025 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
Price Action: Will Avidity Biosciences Inc announce a stock splitJuly 2025 Decliners & Growth Focused Stock Reports - baoquankhu1.vn
Mutual of America Capital Management LLC Trims Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
EFG Asset Management North America Corp. Reduces Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences, Inc. (RNA) Stock Analysis: A Biotech Powerhouse with 434% Revenue Growth and Promising Clinical Trials - DirectorsTalk Interviews
Aug Momentum: Will Avidity Biosciences Inc outperform tech stocksJuly 2025 Review & Stepwise Trade Execution Plans - baoquankhu1.vn
Avidity Biosciences CSO sells $473k in RNA stock By Investing.com - Investing.com South Africa
Avidity Biosciences CFO MacLean sells $329k in stock By Investing.com - Investing.com Australia
Avidity Biosciences CMO sells $354k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Insider Sold Shares Worth $473,388, According to a Recent SEC Filing - 富途资讯
Avidity Biosciences CEO Boyce sells $1.04 million in stock By Investing.com - Investing.com Canada
Avidity Biosciences (NASDAQ:RNA) Insider Sells $473,388.30 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Sells $354,642.75 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) CEO Sells $1,042,338.15 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 2,929 Shares - MarketBeat
Avidity Biosciences CMO sells $354k in stock - Investing.com
Avidity Biosciences CSO sells $473k in RNA stock - Investing.com
Avidity Biosciences stock hits all-time high at $72.70 By Investing.com - Investing.com Australia
Avidity Biosciences CFO MacLean sells $329k in stock - Investing.com
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at $72.70 - Investing.com
Weekly Earnings: Can Kosmos Energy Ltd expand into new marketsQuarterly Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avidity Biosciences Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):